Birth tissueBirth-tissue allografts (amniotic membrane, umbilical cord, placental tissue)

Birth tissue is the collective name for amniotic membrane, amniotic fluid, umbilical cord, and placental tissue recovered after a live, planned caesarean delivery from a consenting mother who has been screened as a living tissue donor. It is regulated by FDA as an HCT/P under 21 CFR 1271, but only when it meets the four 1271.10(a) criteria — minimal manipulation, homologous use, not combined with another article, no systemic effect or dependence on metabolic activity of living cells (with the autologous / first-or-second-degree carve-out).

Recovered tissue is processed into a variety of forms: dehydrated or cryopreserved amniotic membrane sheets for ophthalmic and wound care, micronised amniotic-membrane allografts for orthopaedic and podiatric use, umbilical-cord allografts for soft-tissue reconstruction, and umbilical-cord blood for hematopoietic transplantation (a separately-licensed BLA category).

FDA has issued more warning letters and untitled letters in the birth-tissue space than in any other HCT/P category since 2017. The recurring pattern: a product marketed as a 361 HCT/P that fails one or more of the 1271.10(a) criteria — usually homologous use (amniotic membrane intended for orthopaedic injection is not 'serving the same basic function in the recipient as in the donor'), often more-than-minimal manipulation (micronised, particulated, or expanded products are usually not minimally manipulated), and sometimes both.

An honest 361 birth-tissue product is narrow: amniotic-membrane sheets for ophthalmic surface reconstruction (homologous — the membrane was a barrier in utero and is a barrier on the eye), amniotic-membrane wound covers for surface wounds (homologous — same barrier function), umbilical-cord allografts for vascular reconstruction. Most other use cases require an IND or BLA.

Birth tissue is recovered from a living donor under Subpart C eligibility requirements. The mother is the donor; consent must be informed, documented, and obtained ideally before active labour. Many establishments use a two-step consent — preliminary written consent in the third trimester, confirmation at admission for delivery. Recovery occurs only after a live planned caesarean delivery (vaginal deliveries are generally not used because aseptic recovery is impractical).

• Donor screening — full medical history, sexual contact and behavioural risk screening, infectious-disease testing within the Subpart C windows.
• Maternal IDM panel — minimum: HIV-1/2 (antibody + NAT), HBV (HBsAg + anti-HBc + NAT), HCV (antibody + NAT), syphilis, plus CMV and WNV for viable cellular products.
• Aseptic recovery — recovery technician trained and qualified, sterile field, sterile instruments, transport in validated containers.
• Cord blood collection (if applicable) — concurrent recovery, separate consent, separate processing.
• Chain of custody from delivery room to processing facility with timestamps and signatures.

Birth-tissue processing must remain within the 'minimal manipulation' envelope to preserve 361 status. For amniotic membrane: cleaning, separation from chorion, antibiotic rinse, dehydration or cryopreservation, terminal sterilisation (gamma, e-beam, supercritical CO₂). Cutting to size, mounting on a carrier, packaging in single-use sterile containers — all within minimal manipulation. Decellularisation, particulation below specific size thresholds, and any in vitro expansion typically cross out of 361.

Labelling must include the AATB / ISBT 128 product code, the donation identification number, expiration date, storage conditions, the proper name of the product, and the FDA-required statements for distribution within or across state lines. Marketing claims on the label and in promotional material must stay strictly within the cleared homologous-use indication; non-homologous marketing creates 351-product exposure regardless of how the product was actually processed.